Glomerulonephritis
Publication Date: June 1, 2012
Last Updated: March 14, 2022
Recommendation Statements
Prednisone and prednisolone are equivalent, used in the same dosage, and have both been used in RCTs depending on the country of origin. All later references to prednisone in this chapter refer to prednisone or prednisolone. All later references to oral corticosteroids refer to prednisone or prednisolone.
Steroid-sensitive nephrotic syndrome in children
Treatment of the initial episode of SSNS
We recommend that corticosteroid therapy (prednisone or prednisolone)* be given for at least 12 weeks. (Level 1, B)
312054
We recommend that oral prednisone be administered as a single daily dose (Level 1, B)
312054
starting at 60 mg/m2 /d or 2 mg/kg/d to a maximum 60 mg/d. (Level 1, D)
312054
We recommend that daily oral prednisone be given for 4–6 weeks (Level 1, C)
312054
followed by alternate-day medication as a single daily dose starting at 40 mg/m2 or 1.5 mg/kg (maximum 40 mg on alternate days) (Level 1, D)
312054
and continued for 2–5 months with tapering of the dose. (Level 1, B)
312054
Treatment of relapsing SSNS with corticosteroids
Corticosteroid therapy for children with infrequent relapses of SSNS:
We suggest that infrequent relapses of SSNS in children be treated with a single-daily dose of prednisone 60 mg/m2 or 2 mg/kg (maximum of 60 mg/d) until the child has been in complete remission for at least 3 days. (Level 2, D)
312054
We suggest that, after achieving complete remission, children be given prednisone as a single dose on alternate days (40 mg/m2 per dose or 1.5 mg/kg per dose: maximum 40 mg on alternate days) for at least 4 weeks. (Level 2, C)
312054
Corticosteroid therapy for frequently relapsing (FR) and steroid-dependent (SD) SSNS:
We suggest that relapses in children with FR or SD SSNS be treated with daily prednisone until the child has been in remission for at least 3 days, followed by alternate-day prednisone for at least 3 months. (Level 2, C)
312054
We suggest that prednisone be given on alternate days in the lowest dose to maintain remission without major adverse effects in children with FR and SD SSNS. (Level 2, D)
312054
We suggest that daily prednisone at the lowest dose be given to maintain remission without major adverse effects in children with SD SSNS where alternate-day prednisone therapy is not effective. (Level 2, D)
312054
We suggest that daily prednisone be given during episodes of upper respiratory tract and other infections to reduce the risk for relapse in children with FR and SD SSNS already on alternate-day prednisone. (Level 2, C)
312054
Treatment of FR and SD SSNS with corticosteroid-sparing agents
We recommend that corticosteroid-sparing agents be prescribed for children with FR SSNS and SD SSNS, who develop steroid-related adverse effects. (Level 1, B)
312054
We recommend that alkylating agents, cyclophosphamide or chlorambucil, be given as corticosteroid-sparing agents for FR SSNS. (Level 1, B)
312054
We suggest that alkylating agents, cyclophosphamide or chlorambucil, be given as corticosteroid-sparing agents for SD SSNS. (Level 2, C)
312054
We suggest that cyclophosphamide (2 mg/kg/d) be given for 8–12 weeks (maximum cumulative dose 168 mg/kg). (Level 2, C)
312054
We suggest that chlorambucil (0.1–0.2 mg/kg/d) may be given for 8 weeks (maximum cumulative dose 11.2 mg/kg) as an alternative to cyclophosphamide. (Level 2, C)
312054
We suggest that second courses of alkylating agents not be given. (Level 2, D)
312054
We recommend that levamisole be given as a corticosteroid-sparing agent. (Level 1, B)
312054
We suggest that levamisole be given at a dose of 2.5 mg/kg on alternate days
312054
for at least 12 months (Level 2, C)
312054
since most children will relapse when levamisole is stopped.
We recommend that the calcineurin inhibitors cyclosporine or tacrolimus be given as corticosteroid-sparing agents. (Level 1, C)
312054
We suggest that cyclosporine be administered at a dose of 4–5 mg/kg/d (starting dose) in two divided doses. (Level 2, C)
312054
We suggest that tacrolimus 0.1 mg/kg/d (starting dose) given in two divided doses be used instead of cyclosporine when the cosmetic side-effects of cyclosporine are unacceptable. (Level 2, D)
312054
Monitor CNI levels during therapy to limit toxicity. (NG)
312054
We suggest that CNIs be given for at least 12 months, as most children will relapse when CNIs are stopped. (Level 2, C)
312054
We suggest that MMF be given as a corticosteroid-sparing agent. (Level 2, C)
312054
We suggest that MMF (starting dose 1200 mg/m2 /d) be given in two divided doses for at least 12 months, as most children will relapse when MMF is stopped. (Level 2, C)
312054
We suggest that rituximab be considered only in children with SD SSNS who have continuing frequent relapses despite optimal combinations of prednisone and corticosteroid-sparing agents, and/or who have serious adverse effects of therapy. (Level 2, C)
312054
We suggest that mizoribine not be used as a corticosteroid-sparing agent in FR and SD SSNS. (Level 2, C)
312054
We recommend that azathioprine not be used as a corticosteroid-sparing agent in FR and SD SSNS. (Level 1, B)
312054
Indication for kidney biopsy
Indications for kidney biopsy in children with SSNS are:
- late failure to respond following initial response to corticosteroids;
- a high index of suspicion for a different underlying pathology;
- decreasing kidney function in children receiving CNIs.
312054
Immunizations in children with SSNS
To reduce the risk of serious infections in children with SSNS:
- Give pneumococcal vaccination to the children.
- Give influenza vaccination annually to the children and their household contacts.
- Defer vaccination with live vaccines until prednisone dose is below either 1 mg/kg daily (<20 mg/d) or 2 mg/kg on alternate days (<40 mg on alternate days).
- Live vaccines are contraindicated in children receiving corticosteroid-sparing immunosuppressive agents.
- Immunize healthy household contacts with live vaccines to minimize the risk of transfer of infection to the immunosuppressed child but avoid direct exposure of the child to gastrointestinal, urinary, or respiratory secretions of vaccinated contacts for 3–6 weeks after vaccination.
- Following close contact with Varicella infection, give nonimmune children on immunosuppressive agents varicella zoster immune globulin, if available.
312054
Steroid-resistant nephrotic syndrome in children
Evaluation of children with SRNS
We suggest a minimum of 8 weeks treatment with corticosteroids to define steroid resistance. (Level 2, D)
312054
The following are required to evaluate the child with SRNS:
- a diagnostic kidney biopsy;
- evaluation of kidney function by GFR or eGFR;
- quantitation of urine protein excretion.
312054
Treatment recommendations for SRNS
We recommend using a calcineurin inhibitor (CNI) as initial therapy for children with SRNS. (Level 1, B)
312054
We suggest that CNI therapy be continued for a minimum of 6 months and then stopped if a partial or complete remission of proteinuria is not achieved. (Level 2, C)
312054
We suggest CNIs be continued for a minimum of 12 months when at least a partial remission is achieved by 6 months. (Level 2, C)
312054
We suggest that low-dose corticosteroid therapy be combined with CNI therapy. (Level 2, D)
312054
We recommend treatment with ACE-I or ARBs for children with SRNS. (Level 1, B)
312054
In children who fail to achieve remission with CNI therapy:
be considered in children who fail to achieve complete or partial remission with CNIs and corticosteroids.
- We suggest that mycophenolate mofetil,
312054
- high-dose corticosteroids,
312054
- or a combination of these agents
312054
We suggest that cyclophosphamide not be given to children with SRNS. (Level 2, B)
312054
In patients with a relapse of nephrotic syndrome after complete remission, we suggest that therapy be restarted using any one of the following options: (Level 2, C)
312054
- oral corticosteroids
312054
- return to previous successful immunosuppressive agent
312054
an alternative immunosuppressive agent to minimize potential cumulative toxicity. (Level 2, D)
312054
Minimal-change disease in adults
Treatment of initial episode of adult MCD
We recommend that corticosteroids be given for initial treatment of nephrotic syndrome. (Level 1, C)
312054
We suggest prednisone or prednisolone* be given at a daily single dose of 1 mg/kg (maximum 80 mg) or alternate-day single dose of 2 mg/kg (maximum 120 mg). (Level 2, C)
312054
We suggest the initial high dose of corticosteroids, if tolerated, be maintained for a minimum period of 4 weeks if complete remission is achieved, and for a maximum period of 16 weeks if complete remission is not achieved. (Level 2, C)
312054
In patients who remit, we suggest that corticosteroids be tapered slowly over a total period of up to 6 months after achieving remission. (Level 2, D)
312054
For patients with relative contraindications or intolerance to high-dose corticosteroids (e.g., uncontrolled diabetes, psychiatric conditions, severe osteoporosis), we suggest oral cyclophosphamide or CNIs as discussed in frequently relapsing MCD. (Level 2, D)
312054
We suggest using the same initial dose and duration of corticosteroids for infrequent relapses. (, )
312054
FR/SD MCD
We suggest oral cyclophosphamide 2–2.5 mg/kg/d for 8 weeks. (Level 2, C)
312054
We suggest CNI (cyclosporine 3–5 mg/kg/d or tacrolimus 0.05–0.1 mg/kg/d in divided doses) for 1–2 years for FR/SD MCD patients who have relapsed despite cyclophosphamide, or for people who wish to preserve their fertility. (Level 2, C)
312054
We suggest MMF 500–1000 mg twice daily for 1–2 years for patients who are intolerant of corticosteroids, cyclophosphamide, and CNIs. (Level 2, D)
312054
Corticosteroid-resistant MCD
Re-evaluate patients who are corticosteroid-resistant for other causes of nephrotic syndrome. (NG)
312054
Supportive therapy
We suggest that MCD patients who have AKI be treated with renal replacement therapy as indicated, but together with corticosteroids, as for a first episode of MCD. (Level 2, D)
312054
We suggest that, for the initial episode of nephrotic syndrome associated with MCD, statins not be used to treat hyperlipidemia, and ACE-I or ARBs not be used in normotensive patients to lower proteinuria. (Level 2, D)
312054
Idiopathic focal segmental glomerulosclerosis in adults
Initial evaluation of FSGS
Undertake thorough evaluation to exclude secondary forms of FSGS. (NG)
312054
Do not routinely perform genetic testing. (NG)
312054
Initial treatment of FSGS
We recommend that corticosteroid and immunosuppressive therapy be considered only in idiopathic FSGS associated with clinical features of the nephrotic syndrome. (Level 1, C)
312054
We suggest CNIs be considered as first-line therapy for patients with relative contraindications or intolerance to high-dose corticosteroids (e.g., uncontrolled diabetes, psychiatric conditions, severe osteoporosis). (Level 2, D)
312054
We suggest prednisone be given at a daily single dose of 1 mg/kg (maximum 80 mg) or alternate-day dose of 2 mg/kg (maximum 120 mg). (Level 2, C)
312054
We suggest the initial high dose of corticosteroids be given for a minimum of 4 weeks; continue high-dose corticosteroids up to a maximum of 16 weeks, as tolerated, or until complete remission has been achieved, whichever is earlier. (Level 2, D)
312054
We suggest corticosteroids be tapered slowly over a period of 6 months after achieving complete remission. (Level 2, D)
312054
Treatment for relapse
We suggest that a relapse of nephrotic syndrome is treated as per the recommendations for relapsing MCD in adults. (Level 2, D)
312054
Treatment for steroid-resistant FSGS
For steroid-resistant FSGS, we suggest that cyclosporine at 3–5 mg/kg/d in divided doses be given for at least 4–6 months. (Level 2, B)
312054
If there is a partial or complete remission, we suggest continuing cyclosporine treatment for at least 12 months, followed by a slow taper. (Level 2, D)
312054
We suggest that patients with steroid-resistant FSGS, who do not tolerate cyclosporine, be treated with a combination of mycophenolate mofetil and high-dose dexamethasone. (Level 2, C)
312054
Idiopathic membranous nephropathy
Evaluation of MN
Perform appropriate investigations to exclude secondary causes in all cases of biopsy-proven MN. (NG)
312054
Selection of adult patients with IMN to be considered for treatment with immunosuppressive agents.
We recommend that initial therapy be started only in patients with nephrotic syndrome AND when at least one of the following conditions is met:
- Urinary protein excretion persistently exceeds 4 g/d AND remains at over 50% of the baseline value, AND does not show progressive decline, during antihypertensive and antiproteinuric therapy during an observation period of at least 6 months.
312054
- the presence of severe, disabling, or life-threatening symptoms related to the nephrotic syndrome
312054
- SCr has risen by 30% or more within 6 to 12 months from the time of diagnosis but the eGFR is not less than 25–30 ml/min/1.73 m2 AND this change is not explained by superimposed complications.
312054
Do not use immunosuppressive therapy in patients with a SCr persistently >3.5 mg/dl (>309 lmol/l) (or an eGFR <30 ml/min per 1.73 m2 ) AND reduction of kidney size on ultrasound (e.g., <8 cm in length) OR those with concomitant severe or potentially life-threatening infections. (NG)
312054
Initial therapy of IMN
We recommend that initial therapy consist of a 6-month course of alternating monthly cycles of oral and i.v. corticosteroids, and oral alkylating agents. (Level 1, B)
312054
We suggest using cyclophosphamide rather than chlorambucil for initial therapy. (Level 2, B)
312054
We recommend patients be managed conservatively for at least 6 months following the completion of this regimen before being considered a treatment failure if there is no remission, unless kidney function is deteriorating or severe, disabling, or potentially life-threatening symptoms related to the nephrotic syndrome are present. (Level 1, C)
312054
Perform a repeat kidney biopsy only if the patient has rapidly deteriorating kidney function (doubling of SCr over 1–2 month of observation), in the absence of massive proteinuria (>15 g/d). (NG)
312054
Adjust the dose of cyclophosphamide or chlorambucil according to the age of the patient and eGFR. (NG)
312054
We suggest that continuous daily (noncyclical) use of oral alkylating agents may also be effective, but can be associated with greater risk of toxicity, particularly when administered for >6 months. (Level 2, C)
312054
Alternative regimens for the initial therapy of IMN: CNI therapy
We recommend that cyclosporine or tacrolimus be used for a period of at least 6 months in patients who meet the criteria for initial therapy, but who choose not to receive the cyclical corticosteroid/alkylating-agent regimen or who have contraindications to this regimen. (Level 1, C)
312054
We suggest that CNIs be discontinued in patients who do not achieve complete or partial remission after 6 months of treatment. (Level 2, C)
312054
We suggest that the dosage of CNI be reduced at intervals of 4–8 weeks to a level of about 50% of the starting dosage, provided that remission is maintained and no treatment-limiting CNI-related nephrotoxicity occurs, and continued for at least 12 months. (Level 2, C)
312054
We suggest that CNI blood levels be monitored regularly during the initial treatment period, and whenever there is an unexplained rise in SCr (420%) during therapy. (NG)
312054
Regimens not recommended or suggested for initial therapy of IMN
We recommend that corticosteroid monotherapy not be used for initial therapy of IMN. (Level 1, B)
312054
We suggest that monotherapy with MMF not be used for initial therapy of IMN. (Level 2, C)
312054
Treatment of IMN resistant to recommended initial therapy
We suggest that patients with IMN resistant to alkylating agent/steroid-based initial therapy be treated with a CNI. (Level 2, C)
312054
We suggest that patients with IMN resistant to CNI-based initial therapy be treated with an alkylating agent/ steroid-based therapy. (Level 2, C)
312054
Treatment for relapses of nephrotic syndrome in adults with IMN
We suggest that relapses of nephrotic syndrome in IMN be treated by reinstitution of the same therapy that resulted in the initial remission. (Level 2, D)
312054
We suggest that, if a 6-month cyclical corticosteroid/alkylating-agent regimen was used for initial therapy, the regimen be repeated only once for treatment of a relapse. (Level 2, B)
312054
Treatment of IMN in children
We suggest that treatment of IMN in children follows the recommendations for treatment of IMN in adults. (Level 2, C)
312054
We suggest that no more than one course of the cyclical corticosteroid/alkylating-agent regimen be given in children. (Level 2, D)
312054
Prophylactic anticoagulants in IMN
We suggest that patients with IMN and nephrotic syndrome, with marked reduction in serum albumin (<2.5 g/dl [<25 g/l]) and additional risks for thrombosis, be considered for prophylactic anticoagulant therapy, using oral warfarin. (Level 2, C)
312054
Idiopathic membranoproliferative glomerulonephritis
Evaluation of MPGN
Evaluate patients with the histological (light-microscopic) pattern of MPGN for underlying diseases before considering a specific treatment regimen. (NG)
312054
Treatment of idiopathic MPGN
We suggest that adults or children with presumed idiopathic MPGN accompanied by nephrotic syndrome AND progressive decline of kidney function receive oral cyclophosphamide or MMF plus low-dose alternateday or daily corticosteroids with initial therapy limited to less than 6 months. (Level 2, D)
312054
Infection-related glomerulonephritis
For the following infection-related GN, we suggest appropriate treatment of the infectious disease and standard approaches to management of the kidney manifestations:
- poststreptococcal GN;
- infective endocarditis-related GN;
- shunt nephritis.
312054
Hepatitis C virus (HCV) infection–related GN
For HCV-infected patients with CKD Stages 1 or 2 and GN, we suggest combined antiviral treatment using pegylated interferon and ribavirin as in the general population. (Level 2, C)
312054
Titrate ribavirin dose according to patient tolerance and level of renal function. (NG)
312054
For HCV-infected patients with CKD Stages 3, 4, or 5 and GN not yet on dialysis, we suggest monotherapy with pegylated interferon, with doses adjusted to the level of kidney function. (Level 2, D)
312054
For patients with HCV and mixed cryoglobulinemia (IgG/IgM) with nephrotic proteinuria or evidence of progressive kidney disease or an acute flare of cryoglobulinemia, we suggest either plasmapheresis, rituximab, or cyclophosphamide, in conjunction with i.v. methylprednisolone, and concomitant antiviral therapy. (Level 2, D)
312054
Hepatitis B virus (HBV) infection–related GN
We recommend that patients with HBV infection and GN receive treatment with interferon-α or with nucleoside analogues as recommended for the general population by standard clinical practice guidelines for HBV infection. (Level 1, C)
312054
We recommend that the dosing of these antiviral agents be adjusted to the degree of kidney function. (Level 1, C)
312054
Human Immunodeficiency virus (HIV) infection–related glomerular disorders
We recommend that antiretroviral therapy be initiated in all patients with biopsy-proven HIV-associated nephropathy, regardless of CD4 count. (Level 1, B)
312054
Schistosomal, filarial, and malarial nephropathies
We suggest that patients with GN and concomitant malarial, schistosomal, or filarial infection be treated with an appropriate antiparasitic agent in sufficient dosage and duration to eradicate the organism. (NG)
312054
We suggest that corticosteroids or immunosuppressive agents not be used for treatment of schistosomalassociated GN, since the GN is believed to be the direct result of infection and the attendant immune response to the organism. (Level 2, D)
312054
We suggest that blood culture for Salmonella be considered in all patients with hepatosplenic schistosomiasis who show urinary abnormalities and/or reduced GFR. (Level 2, C)
312054
We suggest that all patients who show a positive blood culture for Salmonella receive anti-Salmonella therapy. (Level 2, C)
312054
Immunoglobulin A nephropathy
Initial evaluation including assessment of risk of progressive kidney disease
Assess all patients with biopsy-proven IgAN for secondary causes of IgAN. (NG)
312054
Assess the risk of progression in all cases by evaluation of proteinuria, blood pressure, and eGFR at the time of diagnosis and during follow-up. (NG)
312054
Pathological features may be used to assess prognosis. (NG)
312054
Antiproteinuric and antihypertensive therapy
We recommend long-term ACE-I or ARB treatment when proteinuria is 41 g/d, with up-titration of the drug depending on blood pressure. (Level 1, B)
312054
We suggest ACE-I or ARB treatment if proteinuria is between 0.5 to 1 g/d (in children, between 0.5 to 1 g/d per 1.73 m2 ). (Level 2, D)
312054
We suggest the ACE-I or ARB be titrated upwards as far as tolerated to achieve proteinuria <1 g/d. (Level 2, C)
312054
In IgAN, use blood pressure treatment goals of <130/80 mmHg in patients with proteinuria <1 g/d, and <125/75 mmHg when initial proteinuria is >1 g/d. (NG)
312054
Corticosteroids
We suggest that patients with persistent proteinuria ≥1 g/d, despite 3–6 months of optimized supportive care (including ACE-I or ARBs and blood pressure control), and GFR ≥50 ml/min per 1.73 m2 , receive a 6-month course of corticosteroid therapy. (Level 2, C)
312054
We suggest not using immunosuppressive therapy in patients with GFR <30 ml/min per 1.73 m2 unless there is crescentic IgAN with rapidly deteriorating kidney function. (Level 2, C)
312054
Immunosuppressive agents (cyclophosphamide, azathioprine, MMF, cyclosporine)
We suggest not treating with corticosteroids combined with cyclophosphamide or azathioprine in IgAN patients (unless there is crescentic IgAN with rapidly deteriorating kidney function.) (Level 2, D)
312054
We suggest not using MMF in IgAN. (Level 2, C)
312054
Other treatments
Fish oil treatment
We suggest using fish oil in the treatment of IgAN with persistent proteinuria ≥1 g/d, despite 3–6 months of optimized supportive care (including ACE-I or ARBs and blood pressure control). (Level 2, D)
312054
Antiplatelet agents
We suggest not using antiplatelet agents to treat IgAN. (Level 2, C)
312054
Tonsillectomy
We suggest that tonsillectomy not be performed for IgAN. (Level 2, C)
312054
Atypical forms of IgAN
MCD with mesangial IgA deposits
We recommend treatment as for MCD in nephrotic patients showing pathological findings of MCD with mesangial IgA deposits on kidney biopsy. (Level 2, B)
312054
AKI associated with macroscopic hematuria
Perform a repeat kidney biopsy in IgAN patients with AKI associated with macroscopic hematuria if, after 5 days from the onset of kidney function worsening, there is no improvement. (NG)
312054
We suggest general supportive care for AKI in IgAN, with a kidney biopsy performed during an episode of macroscopic hematuria showing only ATN and intratubular erythrocyte casts. (Level 2, C)
312054
Crescentic IgAN
Define crescentic IgAN as IgAN with crescents in more than 50% of glomeruli in the renal biopsy with rapidly progressive renal deterioration. (NG)
312054
We suggest the use of steroids and cyclophosphamide in patients with IgAN and rapidly progressive crescentic IgAN, analogous to the treatment of ANCA vasculitis. (Level 2, D)
312054
Henoch-Schönlein purpura nephritis
Treatment of HSP nephritis in children
We suggest that children with HSP nephritis and persistent proteinuria, >0.5–1 g/d per 1.73 m2, are treated with ACE-I or ARBs. (Level 2, D)
312054
We suggest that children with persistent proteinuria, >1 g/d per 1.73 m2 , after a trial of ACE-I or ARBs, and GFR 450 ml/min per 1.73 m2, be treated the same as for IgAN with a 6-month course of corticosteroid therapy. (Level 2, D)
312054
Treatment of crescentic HSP nephritis in children
We suggest that children with crescentic HSP with nephrotic syndrome and/or deteriorating kidney function are treated the same as for crescentic IgAN. (Level 2, D)
312054
Prevention of HSP nephritis in children
We recommend not using corticosteroids to prevent HSP nephritis. (Level 1, B)
312054
HSP nephritis in adults
We suggest that HSP nephritis in adults be treated the same as in children. (Level 2, D)
312054
Lupus nephritis
Class I LN (minimal-mesangial LN)
We suggest that patients with class I LN be treated as dictated by the extrarenal clinical manifestations of lupus. (Level 2, D)
312054
Class II LN (mesangial-proliferative LN)
Treat patients with class II LN and proteinuria <1 g/d as dictated by the extrarenal clinical manifestations of lupus. (Level 2, D)
312054
We suggest that class II LN with proteinuria >3 g/d be treated with corticosteroids or CNIs as described for MCD. (, )
312054
Class III LN (focal LN) and class IV LN (diffuse LN)—initial therapy
- We recommend initial therapy with corticosteroids
312054
combined with either cyclophosphamide (Level 1, B)
312054
or MMF (Level 1, B)
312054
We suggest that, if patients have worsening LN (rising SCr, worsening proteinuria) during the first 3 months of treatment, a change be made to an alternative recommended initial therapy, or a repeat kidney biopsy be performed to guide further treatment. (Level 2, D)
312054
Class III LN (focal LN) and class IV LN (diffuse LN)—maintenance therapy
We recommend that, after initial therapy is complete, patients with class III and IV LN receive maintenance therapy with azathioprine (1.5–2.5 mg/kg/d) or MMF (1–2 g/d in divided doses), and low-dose oral corticosteroids (≤10 mg/d prednisone equivalent). (Level 1, B)
312054
We suggest that CNIs with low-dose corticosteroids be used for maintenance therapy in patients who are intolerant of MMF and azathioprine. (Level 2, C)
312054
We suggest that, after complete remission is achieved, maintenance therapy be continued for at least 1 year before consideration is given to tapering the immunosuppression. (Level 2, D)
312054
If complete remission has not been achieved after 12 months of maintenance therapy, consider performing a repeat kidney biopsy before determining if a change in therapy is indicated. (NG)
312054
While maintenance therapy is being tapered, if kidney function deteriorates and/or proteinuria worsens, we suggest that treatment be increased to the previous level of immunosuppression that controlled the LN. (Level 2, D)
312054
Class V LN (membranous LN)
We recommend that patients with class V LN, normal kidney function, and non–nephrotic-range proteinuria be treated with antiproteinuric and antihypertensive medications, and only receive corticosteroids and immunosuppressives as dictated by the extrarenal manifestations of systemic lupus. (Level 2, D)
312054
We recommend that patients with class V LN, normal kidney function, and non–nephrotic-range proteinuria be treated with antiproteinuric and antihypertensive medications, and only receive corticosteroids and immunosuppressives as dictated by the extrarenal manifestations of systemic lupus. (Level 2, D)
312054
We suggest that patients with pure class V LN and persistent nephrotic proteinuria be treated with corticosteroids plus an additional immunosuppressive agent:
312054
312054
- or MMF
312054
- or azathioprine
312054
General treatment of LN
We suggest that all patients with LN of any class are treated with hydroxychloroquine (maximum daily dose of 6–6.5 mg/kg ideal body weight), unless they have a specific contraindication to this drug. (Level 2, C)
312054
Class VI LN (advanced sclerosis LN)
We recommend that patients with class VI LN be treated with corticosteroids and immunosuppressives only as dictated by the extrarenal manifestations of systemic lupus. (Level 2, D)
312054
Relapse of LN
We suggest that a relapse of LN after complete or partial remission be treated with the initial therapy followed by the maintenance therapy that was effective in inducing the original remission. (Level 2, B)
312054
If resuming the original therapy would put the patient at risk for excessive lifetime cyclophosphamide exposure, then we suggest a non–cyclophosphamide-based initial regimen be used. (Level 2, B)
312054
Consider a repeat kidney biopsy during relapse if there is suspicion that the histologic class of LN has changed, or there is uncertainty whether a rising SCr and/or worsening proteinuria represents disease activity or chronicity. (NG)
312054
Treatment of resistant disease
In patients with worsening SCr and/or proteinuria after completing one of the initial treatment regimens, consider performing a repeat kidney biopsy to distinguish active LN from scarring. (NG)
312054
Treat patients with worsening SCr and/or proteinuria who continue to have active LN on biopsy with one of the alternative initial treatment regimens. (NG)
312054
We suggest that nonresponders who have failed more than one of the recommended initial regimens may be considered for treatment with rituximab, i.v. immunoglobulin, or CNIs. (Level 2, D)
312054
Systemic lupus and thrombotic microangiopathy
We suggest that the antiphospholipid antibody syndrome (APS) involving the kidney in systemic lupus patients, with or without LN, be treated by anticoagulation (target international normalized ratio [INR] 2–3). (Level 2, D)
312054
We suggest that patients with systemic lupus and thrombotic thrombocytopenic purpura (TTP) receive plasma exchange as for patients with TTP without systemic lupus. (Level 2, D)
312054
Systemic lupus and pregnancy
We suggest that women be counseled to delay pregnancy until a complete remission of LN has been achieved. (Level 2, D)
312054
We recommend that cyclophosphamide, MMF, ACE-I, and ARBs not be used during pregnancy. (Level 1, A)
312054
We suggest that hydroxychloroquine be continued during pregnancy. (Level 2, B)
312054
We recommend that LN patients who become pregnant while being treated with MMF be switched to azathioprine. (Level 1, B)
312054
We recommend that, if LN patients relapse during pregnancy, they receive treatment with corticosteroids and, depending on the severity of the relapse, azathioprine. (Level 1, B)
312054
If pregnant patients are receiving corticosteroids or azathioprine, we suggest that these drugs not be tapered during pregnancy or for at least 3 months after delivery. (Level 2, D)
312054
We suggest administration of low-dose aspirin during pregnancy to decrease the risk of fetal loss. (Level 2, C)
312054
LN in children
We suggest that children with LN receive the same therapies as adults with LN, with dosing based on patient size and GFR. (Level 2, D)
312054
Pauci-immune focal and segmental necrotizing glomerulonephritis
Initial treatment of pauci-immune focal and segmental necrotizing GN
We recommend that cyclophosphamide and corticosteroids be used as initial treatment. (Level 1, A)
312054
We recommend that rituximab and corticosteroids be used as an alternative initial treatment in patients without severe disease or in whom cyclophosphamide is contraindicated. (Level 1, B)
312054
Special patient populations
We recommend the addition of plasmapheresis for patients requiring dialysis or with rapidly increasing SCr. (Level 1, C)
312054
We suggest the addition of plasmapheresis for patients with diffuse pulmonary hemorrhage. (Level 2, C)
312054
We suggest the addition of plasmapheresis for patients with overlap syndrome of ANCA vasculitis and anti-GBM GN, according to proposed criteria and regimen for anti-GBM GN. (Level 2, D)
312054
We suggest discontinuing cyclophosphamide therapy after 3 months in patients who remain dialysisdependent and who do not have any extrarenal manifestations of disease. (Level 2, C)
312054
Maintenance therapy
We recommend maintenance therapy in patients who have achieved remission. (Level 1, B)
312054
We suggest continuing maintenance therapy for at least 18 months in patients who remain in complete remission. (Level 2, D)
312054
We recommend no maintenance therapy in patients who are dialysis-dependent and have no extrarenal manifestations of disease. (Level 1, C)
312054
Choice of agent for maintenance therapy
We recommend azathioprine 1–2 mg/kg/d orally as maintenance therapy. (Level 1, B)
312054
We suggest that MMF, up to 1 g twice daily, be used for maintenance therapy in patients who are allergic to, or intolerant of, azathioprine. (Level 2, C)
312054
We suggest trimethoprim-sulfamethoxazole as an adjunct to maintenance therapy in patients with upper respiratory tract disease. (Level 2, B)
312054
We suggest methotrexate (initially 0.3 mg/kg/wk, maximum 25 mg/wk) for maintenance therapy in patients intolerant of azathioprine and MMF, but not if GFR is <60 ml/min per 1.73 m2 . (Level 1, C)
312054
We recommend not using etanercept as adjunctive therapy. (Level 1, A)
312054
Treatment of relapse
We recommend treating patients with severe relapse of ANCA vasculitis (life- or organ-threatening) according to the same guidelines as for the initial therapy. (Level 1, C)
312054
We suggest treating other relapses of ANCA vasculitis by reinstituting immunosuppressive therapy or increasing its intensity with agents other than cyclophosphamide, including instituting or increasing dose of corticosteroids, with or without azathioprine or MMF. (Level 2, C)
312054
Treatment of resistant disease
In ANCA GN resistant to induction therapy with cyclophosphamide and corticosteroids,
- we recommend the addition of rituximab
312054
- and suggest i.v. immunoglobulin
312054
- or plasmapheresis
312054
as alternatives.
Treatment of anti-glomerular basement membrane antibody glomerulonephritis
Treatment of anti-GBM GN
We recommend initiating immunosuppression with cyclophosphamide and corticosteroids plus plasmapheresis in all patients with anti-GBM GN except those who are dialysis-dependent at presentation and have 100% crescents in an adequate biopsy sample, and do not have pulmonary hemorrhage. (Level 1, B)
312054
Start treatment for anti-GBM GN without delay once the diagnosis is confirmed. If the diagnosis is highly suspected, it would be appropriate to begin high-dose corticosteroids and plasmapheresis (Table 31) while waiting for confirmation. (NG)
312054
We recommend no maintenance immunosuppressive therapy for anti-GBM GN. (Level 1, D)
312054
Defer kidney transplantation after anti-GBM GN until anti-GBM antibodies have been undetectable for a minimum of 6 months. (NG)
312054
Recommendation Grading
Overview
Title
Glomerulonephritis
Authoring Organization
Kidney Disease Improving Global Outcomes
Publication Month/Year
June 1, 2012
Last Updated Month/Year
January 8, 2024
Supplemental Implementation Tools
Document Type
Guideline
External Publication Status
Published
Country of Publication
US
Inclusion Criteria
Female, Male, Adolescent, Adult, Child, Infant, Older adult
Health Care Settings
Ambulatory, Hospital, Outpatient
Intended Users
Nurse, nurse practitioner, physician, physician assistant
Scope
Management, Treatment
Diseases/Conditions (MeSH)
D005921 - Glomerulonephritis
Keywords
KDIGO, glomerulonephritis, nephrotic syndrome
Methodology
Number of Source Documents
765
Literature Search Start Date
January 1, 2011
Literature Search End Date
November 1, 2011